gp130/IL-6 Family Cytokine Signaling in Neurodegeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders.
The gp130 family of cytokines constitutes a critical signaling network involved in immune regulation, neuronal survival, and inflammatory responses in the central nervous system. This family includes interleukin-6 (IL-6), interleukin-11 (IL-11), oncostatin M (OSM), leukemia inhibitory factor (LIF), cardiotrophin-1 (CT-1), ciliary neurotrophic factor (CNTF), interleukin-27 (IL-27), and interleukin-35 (IL-35). These cytokines signal through gp130-containing receptor complexes and play complex roles in neurodegenerative diseases.
¶ Receptor Complexes and Signaling Mechanisms
The gp130 family cytokines can signal through two distinct mechanisms:
- Classic Signaling: Membrane-bound receptor signaling where cytokines bind to cell surface receptor complexes
- Trans-Signaling: Soluble cytokine receptors (e.g., sIL-6R) bind cytokine and signal through gp130 on cells lacking the primary receptor, expanding the range of responsive cells
| Receptor | Primary Cytokines | Expression in CNS |
|----------|------------------|-------------------|
| IL-6Rα/gp130 | IL-6 | Neurons, astrocytes, microglia |
| IL-11Rα/gp130 | IL-11 | Astrocytes, neurons |
| OSMR/gp130 | OSM | Astrocytes, microglia |
| LIFR/gp130 | LIF, CT-1, CNTF | Neurons, astrocytes |
| WSX-1/gp130 | IL-27 | Microglia, astrocytes |
| IL-12Rβ2/gp130 | IL-35 | Immune cells |
The primary signaling pathway activated by gp130 cytokines:
- Cytokine binds to receptor complex → gp130 dimerization
- JAK kinases (JAK1, JAK2, TYK2) associated with gp130 become activated
- STAT3 (primarily) and STAT1 become phosphorylated
- STAT dimers translocate to the nucleus
- Target gene transcription including:
- Acute phase proteins
- Anti-apoptotic proteins (Bcl-2, Bcl-xL)
- Negative feedback (SOCS3)
Secondary pathway contributing to cell survival and proliferation:
- Grb2/SOS recruitment to phosphorylated gp130
- Ras activation → RAF → MEK → ERK
- Cell proliferation and differentiation
- Synaptic plasticity modulation
Cell survival pathway activated through gp130 :
- PI3K recruitment to phosphorylated gp130
- Akt activation
- mTOR activation
- Anti-apoptotic effects through Bad phosphorylation
- mTORC1: Protein synthesis, growth
- FOXO: Transcription factor activation
- GSK-3β: Glycogen metabolism
- NF-κB: Survival gene expression
- ERK5: Cardiotrophin-mediated survival
- PLCγ: Calcium signaling
- PKC: Kinase cascades
IL-6 is elevated in Alzheimer's disease brains and CSF:
- Increased IL-6 in hippocampal neurons and surrounding glia
- Correlates with disease severity
- Contributes to chronic inflammatory state
- JAK/STAT3 pathway can influence tau phosphorylation
- IL-6 affects GSK-3β activity
- Neuroinflammation drives tau spread
- Elevated IL-6 in substantia nigra of PD patients
- LIF and CT-1 provide neuroprotection to dopaminergic neurons
- JAK/STAT3 activation promotes survival
- IL-6 drives microglial activation
- Chronic activation contributes to neurotoxicity
- LRRK2 mutations affect cytokine production
- TREM2 variants alter IL-6 responses
- NLRP3 activation: IL-6 promotes inflammasome activation
- Cytokine cascade: IL-6 amplifies inflammatory responses
- Microglial priming: LRRK2 affects activation state
- Inflammation accelerates alpha-synuclein aggregation
- Cytokines can propagate pathology
- Trans-synuclein spread enhanced by inflammatory environment
- Elevated IL-6 in ALS patients and models
- Correlates with disease progression
- Both protective and detrimental effects
- CSF IL-6 as biomarker
- IL-6 signaling in FTD
- FUS pathology and gp130
- Autophagy dysregulation
- Inflammatory endpoints
- Repeat expansion affects signaling
- Dipeptide toxicity
- Immune dysregulation
- IL-6 in lesion formation
- OPC differentiation affected
- Remyelination failure
- IL-6R blockade being explored
- JAK inhibitors in trials
- Astrocytic IL-6 contributes to motor neuron death
- Non-cell autonomous toxicity
- SOCS3 dysregulation affects feedback
- Astrocyte-neuron metabolic coupling disrupted
- Astrocytes respond to gp130 cytokines
- Microglia produce IL-6 family ligands
- Oligodendrocyte survival affected
- NG2 glia respond to signaling
- JAK inhibitors show promise in preclinical models
- Anti-IL-6 strategies being explored
- Modulating trans-signaling vs. classic signaling
| Agent |
Target |
Status |
Indications |
| Tocilizumab |
IL-6R |
Approved (RA) |
Being explored for ALS |
| Sarilumab |
IL-6R |
Approved (RA) |
Preclinical |
| Siltuximab |
IL-6 |
Approved (MCD) |
Being explored |
| Clazakizumab |
IL-6 |
Phase 2 |
Preclinical |
| Agent |
Target |
Status |
| Ruxolitinib |
JAK1/2 |
Clinical trials |
| Tofacitinib |
JAK1/3 |
Preclinical |
| Baricitinib |
JAK1/2 |
Clinical trials |
- Inhibit trans-signaling: Soluble gp130 proteins
- Neutralize cytokines: Antibodies against IL-6, IL-11
- Block receptor binding: IL-6R antagonists
- JAK inhibition: Broad or selective JAK inhibitors
| Marker |
Disease |
Change |
Utility |
| IL-6 |
ALS |
↑ in CSF |
Progression |
| LIF |
PD |
↓ in CSF |
Diagnostic |
| CT-1 |
AD |
↓ in CSF |
Risk marker |
| sIL-6R |
AD |
↑ in serum |
Status |
- CSF/serum ratios for diagnosis
- Longitudinal monitoring
- Treatment response prediction
- Drug development endpoints
flowchart TD
A["Cytokine<br/>IL-6, IL-11, OSM,<br/>LIF, CT-1, CNTF"] --> B["{Classic vs<br/>Trans-Signaling}"]
B["Classic: Membrane<br/>IL-6Rα/gp130"]
B["Trans: Soluble<br/>sIL-6Rα/gp130"]
C --> E["JAK Activation"]
D --> E
E["JAK/STAT3<br/>Pathway"}"]
E["MAPK/ERK<br/>Pathway"}"]
E["PI3K/Akt<br/>Pathway"}"]
F --> I["STAT3 Phosphorylation"]
G --> J["ERK Activation"]
H --> K["Akt Activation"]
I --> L["Nuclear Translocation"]
L --> M["Gene Transcription<br/>Acute Phase Proteins<br/>Anti-apoptotic<br/>SOCS3"]
J --> N["Cell Proliferation<br/>Differentiation"]
K --> O["Cell Survival<br/>mTOR Activation"]
M --> P["Neuroinflammation"]
N --> Q["Synaptic Plasticity"]
O --> R["Neuroprotection"]
P --> S["AD/PD/ALS<br/>Pathology"]
Q --> T["Cognitive Effects"]
R --> U["Neuronal Survival"]